TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 25-Hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficiency of telephone follow-up in solving stoma care problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resuming normal life after hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological support provided by telephone follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severe hypoglycemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Oesophageal acid exposure time (pH < 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total number of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Deep infections
Endpoint domain: Adverse events/effects
Primary endpoint: spontaneous execution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency of visually triggered saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: gain of head movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amplitude of eye and head movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activity ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DF rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rational prescribing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombomodulin plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of leukemia related to benzene exposure
Endpoint domain: Mortality/survival
Primary endpoint: CD4 T cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of hot flashes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot flash score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor pressure at maximum flow (PdetQmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients obstructed by Abrams‐Griffiths classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint congruity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCP angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCP valgus angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-corrected adequate clinical and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident widened spatial QRS‐T angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of bowel symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thickness of the inner fat layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of septae in a direction perpendicular to the skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of gastroduodenal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: end-stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of inflammatory manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived object control skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: actual object control skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol use to a clinically lower level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of multiple IV insertion attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy and safety of ticagrelor monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cecal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcome Scale‐Extended scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Az for visual interpretation of SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Az for visual interpretation of SPECT and 3D-SSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Az for automated diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of salivary S. mutans levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in salivary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in buffer capacity of saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall time-trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Start time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core temperature decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer detection rate
Endpoint domain: Mortality/survival
Primary endpoint: WR of MIBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intention to reduce fat consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to eat more vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence or absence of fevers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nightmare frequency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: symptoms of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: posttraumatic stress disorder (PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shoulder flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scapular substitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean nutrient estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in individual responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse-free survival (RFS) rate at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Microhardness of enamel surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of significant pulmonary vein stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of COX-2 by ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of COX-1 by diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of COX-1 by meloxicam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disc height improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative change in central canal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion rates at 24-month postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HPV (Heart Rate Variability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mood and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tolerability of fasting
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum postprandial systolic BP decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum postprandial diastolic BP decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease of ascending colon volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-prandial plasma levels of amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rates (hSBA titers ≥8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum creatinine (SCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour urinary protein (24 hUpro)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine clearance (CCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable disease duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intelligence Quotient (IQ) decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal memory impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal coding impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in glycated haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of relapse determining conversion to CDMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver understanding and compliance with CPS information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-year LDCR
Endpoint domain: Mortality/survival
Primary endpoint: median number of days to achieve remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer risk associated with pravastatin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of LTB4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined frequency of mortality and severe neurological disability
Endpoint domain: Mortality/survival
Primary endpoint: prevalence of epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum 25OHD levels in infants at 6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein (LDL) cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride to HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: guideline-consistent behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healed biopsy sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of diclofenac-induced epigastric discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gas bloating and flatulence
Endpoint domain: Adverse events/effects
Primary endpoint: Salary cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy rate of predictions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: anti-CS antibody GMC ratios post-dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: frequency of fever within 7 days of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Use of rescue analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean lesion width and height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary levels of caries‐associated microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Death, reinfarction, or target vessel revascularization at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Positive predictive value of PSAD for identifying prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean increase in toe pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of Major Adverse Limb Events (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: muscle protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: global neurocognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Volume difference in lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total attachment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Whole-body 11βHSD1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in the number of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nausea incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Inspiratory Pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SF-36 PCS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial integrity of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of depressive symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Life-threatening psychiatric symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: clinical event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean score on the Modified Mini‐Mental State
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptance of stoma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative pain rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT‐836 dose dependent hematuria
Endpoint domain: Adverse events/effects
Primary endpoint: Glucodynamics (GD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in FEV1 greater than 150 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea in response to sham bronchoconstrictor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of QRP Initiative
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduced analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: memory span performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful venepuncture within 2 attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration required for successful venepuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H‐B facial nerve function grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of occupational injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective assessment of competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self perceived competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical pregnancy rate per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mental functioning
Endpoint domain: Life impact
Endpoint subdomain: Mental functioning
Primary endpoint: % Excess weight loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inotropic score in the first 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FEV1 at 24 and 48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FVC at 24 and 48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: patients' motivation for smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of complete agreement for flare assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of post traumatic amnesia (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention evaluation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: biopsy-proven chronic allograft injury incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean calculated creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: death-censored graft failure
Endpoint domain: Mortality/survival
Primary endpoint: state anxiety improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-efficacy improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in overall treatment satisfaction (DTSQs score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in perceived hypoglycaemia (DTSQc score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in perceived hyperglycaemia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of children with perforation at the end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of children with recurrent perforation during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of examinations with a diagnosis of perforation during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes